Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04979052 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
A Phase 2 study of Candidemia, sponsored by Radboud University Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 6
- Study locations
NCT04979052: Recruiting Phase 2 study of Candidemia, sponsored by Radboud University Medical Center.
NCT04979052 is a Phase 2 study of Candidemia that is actively recruiting participants, run by Radboud University Medical Center. The registered enrollment target is 200 participants, below the 389-participant average among 8 other Candidemia trials with a reported enrollment target (49% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04979052, a Phase 2 study of Candidemia, is actively recruiting participants, sponsored by Radboud University Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 6
- Study locations
Study Summary
A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety and efficacy of rIFN-y treatment in patiens with candidemia.
Conditions Studied
Interventions
- DRUG Interferon Gamma-1B
Study Locations (6)
Other
- Klinikum Der Johann Wolfgang Von Goethe Universitaet - Frankfurt am Main
- Hellenic Institute for the Study of Sepsis (HISS) - Athens
- Universitatea de Medicina si Farmacie luliu Hatieganu - Cluj-Napoca
- Centre Hospitalier Universitaire Vaudois - Lausanne
North Carolina
- Duke University - Durham
Gelderland
- Radboudumc - Nijmegen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What NCT04979052 shows while recruiting
NCT04979052 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 389-participant average among 8 other Candidemia trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Candidemia appearing as the primary indexed condition, and to 1 intervention - of which Interferon Gamma-1B is the first listed.
NCT04979052 lists 6 locations in 3 states (Other, North Carolina, Gelderland).
Frequently Asked Questions
What is clinical trial NCT04979052 about?
NCT04979052 is a clinical study titled "Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia". A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety and efficacy of rIFN-y treatment in patiens with candidemia.
What is the current status of trial NCT04979052?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2022-03-31. Estimated completion is 2026-06-30.
What conditions does trial NCT04979052 study?
This clinical trial studies the following conditions: Candidemia.
What interventions are being tested in trial NCT04979052?
The interventions under investigation include: Interferon Gamma-1B (DRUG).
Who is sponsoring clinical trial NCT04979052?
This trial is sponsored by Radboud University Medical Center, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04979052 being conducted?
This trial has 6 study locations across North Carolina, Gelderland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Candidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04979052's enrollment target sits among peer trials
200 7th of 8 higher than 2 of 8 other Candidemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Candidemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
COMPLETED · Phase 2
-
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
RECRUITING · Phase 3
-
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
ACTIVE NOT RECRUITING · Phase 3
-
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
COMPLETED · Phase 1
-
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
COMPLETED · Phase 3
-
Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI